Scott R. Plotkin, MD, PhD - Basic science and clinical research for NF1, NF2, and schwannomatosis.

  • Lab phone: 617-724-9584
  • Neurology Access Center: 1-855-644-6387

Research Investigator Profile

Dr. Plotkin in suit and tie

Scott R. Plotkin, MD, PhD

  • Assistant Professor of Neurology,
    Harvard Medical School
  • Assistant Neurologist,
    Massachusetts General Hospital
  • Director, Neurofibromatosis Clinic
  • Director, MGH-DFCI-BWH
    Neuro-Oncology Fellowship Program

 

Research Description

Our clinical research group is interested in characterizing the phenotype of patients with tumor suppressor syndromes such as neurofibromatosis (NF).   We are performing whole-body MRI scans in patients to measure the distribution and volume of internal nerve sheath tumors in patients with NF1, NF2, and schwannomatosis.  We are also using laser scanning techniques to measure the number and height of cutaneous tumors in subjects with NF1.  The second clinical research interest is in developing new therapies for patients with NF.  Thus, we are designing and executing clinical trials for these diseases using small molecule inhibitors of growth factor pathways.  The final interest in our group is to understand the genetic basis for schwannomatosis, the third for of NF.  We are studying blood and tumor specimens from these patients to determine the role of the NF2 and INI1 genes in tumor suppression.

Research Lab: Stephen E. and Catherine Pappas Center for Neuro-Oncology

Research interests

Neurofibromatosis, schwannomatosis, primary brain tumors, metastatic brain tumor

Research techniques Clinical trials, mutational analysis, advanced imaging techniques (MRI and PET)
Diseases studied Neurofibromatosis, neuro-oncology
Selected publications
  1. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. N Engl J Med. 2009 Jul 23;361(4):358-67.
  2. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.  Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR.   Radiology. 2009 Mar;250(3):665-73.
  3. Plotkin SR, Singh MA, O’Donnell CC, Harris GJ, McClatchey AI, and Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008;5(7).
  4. Farrell CJ and Plotkin SR. Genetic Causes of Brain Tumors: Neurofibromatosis, Tuberous Sclerosis, Von Hippel-Lindau, and Other Syndromes. In: Wen PY, Schiff D, editors. Neurologic Clinics: brain tumors in adults. 2007;25(4):925-946.
  5. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Ancukiewicz MM, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell. 2007;11(1):83-95.
NCBI PubMed link NCBI PubMed Publications
E-mail address splotkin@partners.org
Lab mailing address Massachusetts General Hospital Cancer Center
Stephen E. & Catherine Pappas Center for Neuro-Oncology
Mailcode: YAW Ste 9E
55 Fruit Street
Boston, MA 02114
Clinical interests Neurofibromatosis, neuro-oncology
Clinical address Pappas Center for Neuro Oncology
55 Fruit Street
YAW 9
Boston, MA 02114

Clinical website address

Neurofibromatosis Clinic

 

Updated 05/17/2011